应用无监督多组学因子分析来揭示与心血管疾病相关的变异模式和分子过程
2024年9月20日
我们提出了一种灵活、可扩展的基于 Jupyter 实验室的工作流程，用于复杂多组学数据集的无监督分析，该工作流程结合了不同的预处理步骤、多组学因子分析模型的估计和多种下游分析。
我们的工作流程可以轻松分析不同分辨率的复杂多组学数据集。该方法提取变体的主要模式，这些变体要么是唯一的，要么是与特定数据类型共享的，并将它们聚合起来。由此产生的所谓因素可以与分子过程和临床或技术协变量联系起来。
我们的分析是最早将 MOFA 模型应用于多个样本的多组学和单细胞数据的分析之一。重要的是，这些样本来自心脏病发作患者的临床队列。这使我们能够识别与结果和疾病状态相关的多细胞免疫特征。
因此，单细胞和多组学数据集的可用性增加，但通常，这些数据集的特征仅单独分析。这限制了洞察力，因为通常，生物过程是多种特征和细胞类型之间相互作用的结果。使用我们的实验方案，用户可以轻松地对整个数据集进行综合分析并识别这些多细胞程序。
我们认为将此协议应用于其他多组学数据集将产生对其他疾病或背景的新见解。这些见解将为未来的生物标志物或治疗研究提供信息。
概览
本文介绍了一个灵活、可扩展的基于Jupyter-lab的无监督复杂多组学数据集分析工作流程。该工作流程能够提取与分子过程和临床共变量相关的变异主要模式。
关键研究组成部分
科学领域
- 多组学分析
- 临床研究
- 数据分析方法
背景
- 多组学数据集的分辨率和复杂性可能各不相同。
- 理解不同数据类型之间的关系对生物医学研究至关重要。
- 之前的方法在分析此类数据集方面缺乏灵活性。
- 临床队列为疾病机制提供了宝贵的见解。
研究目的
- 开发分析多组学数据集的工作流程。
- 识别与临床结果相关的多细胞免疫特征。
- 将MOFA模型应用于多组学和单细胞数据。
使用的方法
- 多组学数据集的无监督分析。
- 多组学因子分析（MOFA）模型的估计。
- 不同预处理步骤的整合。
- 将因子与临床共变量联系起来的下游分析。
主要结果
- 跨数据类型识别独特和共享模式。
- 将因子与分子过程和临床结果联系起来。
- 对心脏病发作患者的免疫特征的见解。
- 证明了工作流程在临床研究中的有效性。
结论
- 开发的工作流程增强了复杂数据集的分析。
- 它提供了一个将多组学数据与临床见解联系起来的强大框架。
- 这种方法可以应用于各种生物医学研究背景。
常见问题
Executive Industry Relevance
Integrating unsupervised multi-omic factor analysis (MOFA) into discovery-stage workflows enables biopharma teams to uncover complex molecular patterns and multicellular programs underlying cardiovascular disease. This approach enhances predictive confidence by linking high-dimensional omics data to disease-relevant processes, supporting early target validation and translational biomarker discovery. The workflow's scalability and adaptability position it as a reusable capability for portfolio-wide mechanistic de-risking and prioritization.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of multicellular immune signatures associated with disease states.
- Supports functional target validation by integrating diverse omics and clinical covariates.
- Facilitates biological de-risking through identification of shared and unique molecular factors.
- Improves predictive confidence for target selection and triage decisions.
Screening & Assay Development
- Prepares harmonized, quality-controlled multi-omics datasets for downstream analysis.
- Standardizes data integration and normalization across assays and timepoints.
- Generates quantitative factor outputs suitable for comparative screening and hypothesis testing.
- Enables reproducible extraction of molecular patterns for assay development.
Translational & Preclinical Research
- Aligns molecular factors with clinical phenotypes and disease progression.
- Supports continuity from discovery through preclinical biomarker validation.
- Informs risk-adjusted advancement by linking omics signatures to patient subgroups.
- Provides mechanistic insights for translational research in cardiovascular and other diseases.
Pipeline & Workflow Integration
This MOFA-based workflow bridges early discovery, lead identification, and translational research by enabling integrated analysis of multi-omics and clinical data.
- Discovery Biology: Supports hypothesis testing and pathway clarification by extracting major axes of molecular variation.
- Screening: Delivers harmonized, quantitative outputs for robust assay readiness and reproducibility.
- Analytics: Provides statistical decomposition of variance and factor association with clinical covariates.
- Translational Research: Connects molecular patterns to disease states and patient outcomes for biomarker alignment.
- Enterprise Reuse: Offers a scalable, adaptable workflow applicable to diverse multi-omics datasets and disease contexts.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation.
- Operational Value: Standardizes multi-omics data processing and analysis for reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio management.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of discovery programs.
Implementation Considerations
- Requires expertise in multi-omics data integration and statistical modeling.
- Depends on robust computational infrastructure and Jupyter-based workflow management.
- Necessitates standardized data pre-processing and harmonization across assays.
- Adaptable to various omics platforms and disease-relevant model systems.
- Limited by input data quality and the complexity of clinical covariates included.
